Patent intelligence · US
US 8481511
Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
Patent details — US 8481511
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 9, 2013
- Expiration
- Jul 4, 2033
- Claims
- 9
- CPC classes
- A61K, A61K31/337, A61K47/6951, A61K9/0019
Quick answer
US 8481511 (Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process) is held by Hainan Hdeton Science and Technology Co., Ltd.. Status: granted. Granted Jul 9, 2013. Expires Jul 4, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/337, A61K47/6951, A61K9/0019, A61P, A61P35/00
More from Hainan Hdeton Science and Technology Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12419831
Hydrocortisone oral liquid formulations
granted -
US 12396974
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
granted -
US 12357582
Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
granted -
US 12343324
Dihydromyricetin hot melt extrusion formulations and methods for forming them
granted -
US 12329816
Immunotherapy with metabolic enzyme expression
granted -
US 12209256
System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction
granted -
US 12195768
System and method for modulating stress granule assembly
granted -
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted
Related coverage
Frequently asked questions
What is US patent 8481511?
US 8481511 (Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process) is held by Hainan Hdeton Science and Technology Co., Ltd.. Status: granted. Granted Jul 9, 2013. Expires Jul 4, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8481511?
Hainan Hdeton Science and Technology Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 163 pharmaceutical patents for this assignee.
When does US 8481511 expire?
Our index shows an expiration date of Jul 4, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.